Montelukast Use Decreases Cardiovascular Events in Asthmatics
Cysteinyl leukotrienes are proinflammatory mediators with a clinically established role in asthma and a human genetic and preclinical role in cardiovascular pathology. Given that cardiovascular disease has a critical inflammatory component, the aim of this work was to conduct an observational study...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.611561/full |
| _version_ | 1829494693822464000 |
|---|---|
| author | Malvina Hoxha Malvina Hoxha Calogero C. Tedesco Silvana Quaglin Visar Malaj Linda Pustina Valerie Capra Jilly F. Evans Angelo Sala Angelo Sala G. Enrico Rovati |
| author_facet | Malvina Hoxha Malvina Hoxha Calogero C. Tedesco Silvana Quaglin Visar Malaj Linda Pustina Valerie Capra Jilly F. Evans Angelo Sala Angelo Sala G. Enrico Rovati |
| author_sort | Malvina Hoxha |
| collection | DOAJ |
| description | Cysteinyl leukotrienes are proinflammatory mediators with a clinically established role in asthma and a human genetic and preclinical role in cardiovascular pathology. Given that cardiovascular disease has a critical inflammatory component, the aim of this work was to conduct an observational study to verify whether the use of a cysteinyl leukotriene antagonist, namely, montelukast, may protect asthmatic patients from a major cardiovascular event and, therefore, represent an innovative adjunct therapy to target an inflammatory component in cardiovascular disease. We performed an observational retrospective 3-year study on eight hundred adult asthmatic patients 18 years or older in Albania, equally distributed into two cohorts, exposed or nonexposed to montelukast usage, matched by age and gender according to information reported in the data collection. Patients with a previous history of myocardial infarction or ischemic stroke were excluded. In summary, 37 (4.6%) of the asthmatic patients, 32 nonexposed, and five exposed to montelukast suffered a major cardiovascular event during the 3-year observation period. All the cardiovascular events, in either group, occurred among patients with an increased cardiovascular risk. Our analyses demonstrate that, independent from gender, exposure to montelukast remained a significant protective factor for incident ischemic events (78% or 76% risk reduction depending on type of analysis). The event-free Kaplan–Meier survival curves confirmed the lower cardiovascular event incidence in patients exposed to montelukast. Our data suggest that there is a potential preventative role of montelukast for incident cardiac ischemic events in the older asthmatic population, indicating a comorbidity benefit of montelukast usage in asthmatics by targeting cysteinyl leukotriene-driven cardiac disease inflammation. |
| first_indexed | 2024-12-16T06:56:38Z |
| format | Article |
| id | doaj.art-d5bfab8ff59649f7890c5f2ef03e7fc7 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-16T06:56:38Z |
| publishDate | 2021-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-d5bfab8ff59649f7890c5f2ef03e7fc72022-12-21T22:40:16ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-01-011110.3389/fphar.2020.611561611561Montelukast Use Decreases Cardiovascular Events in AsthmaticsMalvina Hoxha0Malvina Hoxha1Calogero C. Tedesco2Silvana Quaglin3Visar Malaj4Linda Pustina5Valerie Capra6Jilly F. Evans7Angelo Sala8Angelo Sala9G. Enrico Rovati10Department of Pharmaceutical Sciences, University of Milan, Milano, ItalyDepartment for Chemical-Toxicological and Pharmacologicsal Evaluation of Drugs, Catholic University Our Lady of Good Counsel, Tirana, AlbaniaCentro Cardiologico Monzino IRCCS, Milan, ItalyDepartment of Industrial Engineering and Information, University of Pavia, Pavia, ItalyDepartment of Economics, Faculty of Economics, University of Tirana, Tirana, AlbaniaMinistry of Education and Sports, Tirana, AlbaniaDepartment of Pharmaceutical Sciences, University of Milan, Milano, ItalyUniversity of Pennsylvania School of Medicine, Philadelphia, PA, United StatesDepartment of Pharmaceutical Sciences, University of Milan, Milano, ItalyIBIM, Consiglio Nazionale Delle Ricerche, Palermo, ItalyDepartment of Pharmaceutical Sciences, University of Milan, Milano, ItalyCysteinyl leukotrienes are proinflammatory mediators with a clinically established role in asthma and a human genetic and preclinical role in cardiovascular pathology. Given that cardiovascular disease has a critical inflammatory component, the aim of this work was to conduct an observational study to verify whether the use of a cysteinyl leukotriene antagonist, namely, montelukast, may protect asthmatic patients from a major cardiovascular event and, therefore, represent an innovative adjunct therapy to target an inflammatory component in cardiovascular disease. We performed an observational retrospective 3-year study on eight hundred adult asthmatic patients 18 years or older in Albania, equally distributed into two cohorts, exposed or nonexposed to montelukast usage, matched by age and gender according to information reported in the data collection. Patients with a previous history of myocardial infarction or ischemic stroke were excluded. In summary, 37 (4.6%) of the asthmatic patients, 32 nonexposed, and five exposed to montelukast suffered a major cardiovascular event during the 3-year observation period. All the cardiovascular events, in either group, occurred among patients with an increased cardiovascular risk. Our analyses demonstrate that, independent from gender, exposure to montelukast remained a significant protective factor for incident ischemic events (78% or 76% risk reduction depending on type of analysis). The event-free Kaplan–Meier survival curves confirmed the lower cardiovascular event incidence in patients exposed to montelukast. Our data suggest that there is a potential preventative role of montelukast for incident cardiac ischemic events in the older asthmatic population, indicating a comorbidity benefit of montelukast usage in asthmatics by targeting cysteinyl leukotriene-driven cardiac disease inflammation.https://www.frontiersin.org/articles/10.3389/fphar.2020.611561/fullasthmamontelukastinflammationcardiovascular diseasesleukotriene receptors |
| spellingShingle | Malvina Hoxha Malvina Hoxha Calogero C. Tedesco Silvana Quaglin Visar Malaj Linda Pustina Valerie Capra Jilly F. Evans Angelo Sala Angelo Sala G. Enrico Rovati Montelukast Use Decreases Cardiovascular Events in Asthmatics Frontiers in Pharmacology asthma montelukast inflammation cardiovascular diseases leukotriene receptors |
| title | Montelukast Use Decreases Cardiovascular Events in Asthmatics |
| title_full | Montelukast Use Decreases Cardiovascular Events in Asthmatics |
| title_fullStr | Montelukast Use Decreases Cardiovascular Events in Asthmatics |
| title_full_unstemmed | Montelukast Use Decreases Cardiovascular Events in Asthmatics |
| title_short | Montelukast Use Decreases Cardiovascular Events in Asthmatics |
| title_sort | montelukast use decreases cardiovascular events in asthmatics |
| topic | asthma montelukast inflammation cardiovascular diseases leukotriene receptors |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2020.611561/full |
| work_keys_str_mv | AT malvinahoxha montelukastusedecreasescardiovasculareventsinasthmatics AT malvinahoxha montelukastusedecreasescardiovasculareventsinasthmatics AT calogeroctedesco montelukastusedecreasescardiovasculareventsinasthmatics AT silvanaquaglin montelukastusedecreasescardiovasculareventsinasthmatics AT visarmalaj montelukastusedecreasescardiovasculareventsinasthmatics AT lindapustina montelukastusedecreasescardiovasculareventsinasthmatics AT valeriecapra montelukastusedecreasescardiovasculareventsinasthmatics AT jillyfevans montelukastusedecreasescardiovasculareventsinasthmatics AT angelosala montelukastusedecreasescardiovasculareventsinasthmatics AT angelosala montelukastusedecreasescardiovasculareventsinasthmatics AT genricorovati montelukastusedecreasescardiovasculareventsinasthmatics |